We've known from the beginning (that is, since 2018) that the TLX trial had significantly fewer patients compared to Pluvicto. So, I'm perplexed to see the market using this argument to justify today's drop.
Ann: Q3 2023 Business Update to Accompany Quarterly Results, page-74
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.45 |
Change
0.520(2.48%) |
Mkt cap ! $7.178B | |||
| Open | High | Low | Value | Volume |
| $20.83 | $21.50 | $20.80 | $17.54M | 824.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2037 | $21.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.50 | 12320 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |